Regdanvimab vs placebo
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 1 participantsLow
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
Remdesivir and standard care may leads to lower serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
The review found no eligible studies for this question.
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).